TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04845906

Intervention type: DEVICE
Intervention: StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)
Description: Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
Study: NCT06552728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Healing
Description: EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
Study: NCT06717633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: The ESWT will be administered using an ESWT device (Modus ESWT Compact Model-Portable) once weekly over three consecutive weeks, resulting in a total of three sessions. A radial shockwave mode was chosen for the therapy. During each session, participants will receive 3000 pulses at an 12-Hz frequency and pneumatic pressure of 2.5 bars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: The MLS (Multiwave Locked System) laser is a specific type of low-level laser therapy (LLLT) that combines two different wavelengths of light-typically 808 nm (near-infrared) and 905 nm (mid-infrared)-to produce therapeutic effects. These wavelengths are delivered simultaneously in a synchronized manner, which is intended to enhance the overall effectiveness of the treatment. LLLT will be conducted with the laser device (MLS Laser M6 Robotic Multiwave Lock System, Asalaser, Italy) with the use of protective goggles, and the treatment parameters were set as follows: 100% power, 3 Joules per treatment spot with 904 nm wavelength, and a treatment area of 20 cm². The LLLT will be applied to five points on the anterior part of the joint space, with each point treated for 3 minutes, totaling 15 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field therapy
Description: For PEMF, the applicator of the device (Easy QS Magnetotherapy Portable Magnetotherapy Medical Device, Asalaser, Italy) will be positioned to target the medial and lateral aspects of the knee. The treatment parameters were defined as follows: rectangular field shape, 30 Hz frequency, 10 mT intensity, and a duration of 20 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
Study: NCT06719154

Intervention type: DEVICE
Intervention: Profhilo Structura
Description: 2 injections (30 days apart) of investigated medical device into superficial fat compartments of zygomatic arch and preauricular area

Intervention type: OTHER
Intervention: Sham (No Treatment)
Description: Sham (No Treatment)
Study: NCT06715137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight.
Study: NCT06718569

Intervention type: DRUG
Intervention: Biological or targeted synthetic DMARD
Description: All biological or targeted synthetic DMARDs that are available for treatment of patients with inflammatory joint diseases
Study: NCT06717464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenous injection, q3w, for 54 weeks (18 cycles)
Study: NCT06715293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopill
Description: Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemopill
Description: Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OGD
Description: OGD will be performed to compare the results of the hemopill

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OGD
Description: OGD will be performed to compare the results of the hemopill
Study: NCT06715332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colorectal ESD with SpydrBlade Flex
Description: The allocated intervention would be performed under sedation or monitored anaesthesia by experienced endoscopists with at least 50 case experience of colon ESD.~Colon ESD procedure would be performed as per described in the literature. After submucosal injection of solution to create a cushion, mucosal incision and submucosal dissection would be performed with the SydrBlade Flex. Submucosal plane dissection will be performed using the SpydrBlade Flex (BRF, cutting frequency 400kHz, power setting 35W). The exact resection strategy would be according to the endoscopists' preference, including different adjunctive techniques such as countertraction, tunnelling or pocket creation method. Upon completion of ESD, the resultant mucosal defect would be examined for any perforation or bleeding.
Study: NCT06718777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.1% polyhexanide Care
Description: After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.1% polyhexanide solution. Then, 2 treatments were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care and four follow-ups were performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9 % NaCl Care
Description: After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.9% sodium chloride. Then, 2 care sessions were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care sessions and four follow-ups were performed.
Study: NCT06717997

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound
Description: The placenta thickness will be performed on transabdominal images obtained in a longitudinal plane. Three measurements will be performed at the thickest portion of the placenta. The average of these three measurements was used for statistical analysis. The cohorts will be classified into 1) thick placenta (\>4 cm) and average placenta (2-4 cm).

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound
Description: The placenta thickness will be performed on transabdominal images obtained in a longitudinal plane. Three measurements will be performed at the thickest portion of the placenta. The average of these three measurements was used for statistical analysis. The cohorts will be classified into 1) thick placenta (\>4 cm) and average placenta (2-4 cm).
Study: NCT06718543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 with SCRT and CapeOX
Description: In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7day interval, patients will receive 2 cycles of CapeOX chemotherapy combined with AK112 (every 3 weeks; Day 1: Oxaliplatin, 130 mg/m², IV infusion; Day 1: AK112, 20 mg/kg, IV infusion; Day 1 to Day 14: Capecitabine, 850-1000 mg/m², BID, orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 with SCRT
Description: In the 1st week, neoadjuvant short-course radiotherapy will be administered (25 Gy in 5 fractions over 5 days). After a 7-day interval, patients will receive 2 cycles of AK112 treatment (Day 1: AK112, 20 mg/kg, IV infusion).
Study: NCT04159493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: Vaginal Application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Application
Study: NCT05266066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical observation without antibiotic therapy for VAT
Description: Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 day antibiotic course for VAT
Description: Patients will receive standard care plus 7 day course of antibiotic.
Study: NCT05291104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid, choline chloride
Description: In this study, we divide intervention group into two groups which received folic acid (FA) or choline chloride (CC) supplement. Each subgroups contain 20 subjects, including 10 men and women. According to Recommended Daily Nutrient Allowance, FA recommended intake is 400 ug / day and choline recommended intake in men and women is 450 and 390 mg / day. From phase 1 to phase 3 stage, for every 10 days, subjects are given 2-fold, 4-fold and 8-fold recommended intake dose of FA or CC. All supplement solve in 240 ml cranberry juice.
Study: NCT05763524

Intervention type: PROCEDURE
Intervention: Adrenalectomy with or without lymphadenectomy
Description: Regarding lymphadenectomy extent, it will be described as locoregional or systematic depending on availability of data in the Eurocrine database.
Study: NCT05281679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction group (L-BFR)
Description: The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity resistance exercise without blood flow restriction group (H-BFR).
Description: The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
Study: NCT05140954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 25mg TAF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 25mg TAF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
Study: NCT05195749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 101-PGC-005 ('005) + SOC
Description: Three consecutive days of '005 administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: Three consecutive days of placebo administration
Study: NCT05140954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 25mg TAF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
Study: NCT05102396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical oxybutynin spray
Description: Participants will receive topical oxybutynin spray (10%).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo spray
Description: Participants will receive topical placebo spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral oxybutynin
Description: Participants will receive oxybutynin (tablets).
Study: NCT05741476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBV712
Description: DBV712 250 mcg epicutaneous system.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DBV712 matching placebo epicutaneous system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBV712
Description: DBV712 250 mcg epicutaneous system.
Study: NCT04640142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Newnorm
Description: Newnorm is a 20% human normal immunoglobulin for SC infusion.
Study: NCT05426317

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: This study only involves the patient taking 5 additional blood tests (peripheral venipuncture) compared to his usual care, which will be taken when he comes to the hospital. Each sample only requires a blood volume of 5mL (one tube), or a total blood volume of 25mL for the study (one blood test every 3 months for one year).
Study: NCT06472388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 5 MG
Description: oral everolimus 5 mg/daily
Study: NCT05520593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex Carbohydrate Drink
Description: Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
Study: NCT06472388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 5 MG
Description: oral everolimus 5 mg/daily
Study: NCT06514937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Training
Description: Emotional Training Therapy following the programme in the computer
Study: NCT05188118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60mg oral once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg intravenous once every 3 weeks over 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg intravenous once every 3 weeks over 12 weeks, then 480mg once every 4 weeks after

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 18mg oral once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 5mg oral once daily for 12 weeks
Study: NCT06285786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic Training on Patient Handling Techniques
Description: Each participant will receive an ergonomic training on proper patient handling technique, adhering to the appropriate program to use with the SAMS bed and the Vendlet between session 1 \& 2.~In small groups of 6-10 participants, a healthcare ergonomist (M. Leger) will be responsible to demonstrate, instruct and evaluate each participant on all 4 techniques on the SAMS bed. Each participant will have multiple opportunities to demonstrate their skills.~In the same session, each participant will also receive proper training from a specialized occupational therapist on how to use the Vendlet. Each participant will have multiple opportunities to demonstrate their skills.~After completing the intervention, each participant will be prepared to participate in the post-intervention data collection session in the laboratory.
Study: NCT04821219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment prediction PDT platform
Description: PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.
Study: NCT05993351

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: All participants will have 3 MRI scanning sessions to track brain health over time following the same protocol each time. The MRI sessions will occur acutely (\<2 weeks post-concussion), 3-months and 6-months post-concussion. A series of MRI scans will be acquired including T1, T2, T2-FLAIR, SWI, ASL, rsfMRI, and DTI scans to characterize structural, microstructural, functional and tissue perfusion changes within the brain over time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine and saliva samples
Description: At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine and saliva samples
Description: At each study visit all participants will be asked to provide small urine and saliva samples for a metabolomic analysis using a high throughput multi-segment injection-capillary electrophoresis-mass spectrometry technology. This will allow for rapid non-targeted analysis of polar/hydrophilic metabolites, as well as non-polar/ionic lipids with stringent quality control.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The Post-Concussion Symptom Scale (PCSS) and the Depression Anxiety Stress Scale (DASS-42) will be used to assess the self-reported presence and severity of known concussion-related symptoms.
Study: NCT05075941

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Intervention type: OTHER
Intervention: Vaccination coverage
Description: proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population
Study: NCT05533515

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC Blood Test
Description: We will draw blood to measure the level of Circulating Tumour Cells
Study: NCT05305846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA-PROTO2
Description: During urodynamics, the TENA-PROTO2 will be positioned onto the lower abdomen of patients to collect raw data for the continuous development of the future ultrasound bladder sensor.
Study: NCT05320666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yes You Can…Make Smart Choices! (YYC…MSC!) program
Description: The YYC...MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.
Study: NCT06261606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid strategy
Description: A hybrid strategy inclusive of:~1. A one-page flashcard describing the adverse cardiovascular effects of air pollution and individual-level strategies to mitigate these effects~2. Alerting patients on polluted days (defined as air quality index (AQI) ≥ 131 \[33\]) by sending cell phone text messages and recommending to not go outdoors or minimize outdoor activities (especially exercising) on those days. This will also be accompanied by periodic phone calls to ascertain that the patients receive the messages and are attentive to them.~3. Wearing KN-95 facemasks (provided by the investigators of this study) as a physical barrier against air pollution on highly polluted days (defined as AQI ≥ 131) in case the patient cannot avoid going outdoors~4. Dietary intervention by encouraging patients to consume citrus fruits during days with AQI ≥ 131